EXAGEN INC. (XGN) Gross Margin
- Gross margin · 12 months: Value 58.64%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 58.64% | Gross profit / revenue. Period ending 2026-06-30. $41.70M ÷ $71.12M × 100 ≈ 58.64% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 41.70M USD | Gross Profit |
| Revenue | 71.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 29.42M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $41.70M | $71.12M | $29.42M | 58.64% |
| 2026-03-31 | $39.88M | $68.38M | $28.50M | 58.32% |
| 2025-12-31 | $38.80M | $66.58M | $27.78M | 58.28% |
| 2025-09-30 | $38.07M | $63.60M | $25.53M | 59.86% |
| 2025-06-30 | $34.98M | $58.86M | $23.89M | 59.42% |
| 2025-03-31 | $33.64M | $56.72M | $23.09M | 59.30% |
| 2024-12-31 | $33.11M | $55.64M | $22.53M | 59.51% |
| 2024-09-30 | (m) | $55.75M | $22.97M | (m) |
| 2024-06-30 | (m) | $56.66M | $23.16M | (m) |
| 2024-03-31 | (m) | $55.73M | $22.98M | (m) |
| 2023-12-31 | (m) | $52.55M | $23.09M | (m) |
| 2023-09-30 | (m) | $51.62M | $23.78M | (m) |
| 2023-06-30 | (m) | $52.93M | $24.08M | (m) |
| 2023-03-31 | (m) | $46.40M | $24.32M | (m) |
| 2022-12-31 | (m) | $45.56M | $24.21M | (m) |
| 2022-09-30 | (m) | $45.41M | $22.84M | (m) |
| 2022-06-30 | (m) | $44.30M | $22.32M | (m) |
| 2022-03-31 | (m) | $48.11M | $21.69M | (m) |
| 2021-12-31 | (m) | $48.30M | $20.59M | (m) |
| 2021-09-30 | (m) | $48.28M | $19.98M | (m) |
| 2021-06-30 | (m) | $46.80M | $18.84M | (m) |
| 2021-03-31 | (m) | $42.98M | $16.73M | (m) |
| 2020-12-31 | (m) | $41.98M | $16.56M | (m) |
| 2020-09-30 | (m) | $39.52M | $16.82M | (m) |
| 2020-06-30 | (m) | $39.19M | $17.26M | (m) |
| 2020-03-31 | (m) | $40.71M | $18.91M | (m) |
| 2019-12-31 | (m) | $40.39M | $18.81M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $32.44M | $15.38M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |